References
- 1. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003; 24(3): 261–271
- 2. Vranic A, Simovic S, Ristic P, Nikolic T, Stojic I, Srejovic I et al. The acute effects of different spironolactone doses oncardiac function in streptozotocin-induced diabetic rats. Can J Physiol Pharmacol 2017; 95: 1343–1350
- 3. Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens 2012; 21: 147–156
- 4. Nguyen Dinh Cat A, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal 2013; 19: 1110-1120
- 5. Nguyen Dinh Cat A, Touyz RM. Cell signaling of angiotensin II on vasculartone: novel mechanisms. Curr Hypertens Rep 2011; 13: 122–128
- 6. Kintscher U, Marx N, Martus P, Stoppelhaar M, Schimkus J, Schneider A et al. Effect ofhigh-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension. Diabetes Res Clin Pract 2010; 89: 209–215
- 7. Ristic P, Srejovic I, Nikolic T, Stojic I, Ristic D, Zivkovic V et al. The effects of zofenopril on cardiac function and pro-oxidative parameters in the streptozotocin-induced diabetic rat heart. Mol Cell Biochem 2017; 426: 183–193
- 8. Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA et al. Effect ofnateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463–1476
- 9. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients. the VALUE trial J Hypertens 2006; 24: 1405–1412
- 10. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882–1885
- 11. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64: 2537–2565
- 12. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L. Blood pressure dependent and independent effects of antihypertensive treatment onclinical events in the VALUE Trial Lancet 2004; 363: 2049–2051
- 13. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921–1926
- 14. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003; 285: 117–124
- 15. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103: 799–805
- 16. Kim HJ, Han SJ, Kim DJ, Jang HC, Lim S, Choi SH et al. Effects of valsartan andamlodipine on oxidative stress in type 2 diabetic patients with hypertension: arandomized, multicenter study. Korean J Intern Med 2017; 32: 497–504
- 17. Jung KH, Chu K, Lee ST, Kim SJ, Song EC, Kim EH et al. Blockade of AT1 receptorreduces apoptosis, inflammation, and oxidative stressin normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 2007; 322: 1051–1058
- 18. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulatesmarkers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440– 444
- 19. Shmiedr R, Hilgers KF, Schlaich MP, Shmidt BMW. Renin-angiotensin system and cardiovascular risk, Lancet 2007; 369(9568): 1208–1219
- 20. Yang ZH, Peng XD. Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus. Chin Med J 2010; 123: 3640–3643
- 21. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology 2007; 12: 261–266
- 22. Auclair C, Voisin E. Nitroblue tetrazolium reduction. In: Greenwald RA (ed) CRC handbook of methods for oxygen radical research. Boca Raton CRC Press, 1985: 123–132
- 23. Green LC, Wagnwr DA, Glogowski J, Skipper PL, Wish-nok JS, Tannenbaum SR. Analysis of nitrate, nitrite and (15 N) nitrate in biological fluids. Anal Biochem 1985; 126: 131–138
- 24. Pick E, Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J Immunol Methods 1980; 38: 161–170
- 25. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351–358
- 26. Goyal SN, Reddy NM, Patil KR, Nakhate KT, Ojha S, Patil CR et al. Challenges and issues with streptozotocin-induced diabetes—A clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics. Chem Biol Interact 2016; 244: 49–63
- 27. Chan P, Wong KL, Liu IM, Tzeng TF, Yang TL et al. Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats. J Hypertens 2003; 21; 761–769
- 28. Criscione L, De Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1–receptor subtype. Br J Pharmacol 1993; 110: 7617–7671
- 29. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031
- 30. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766
- 31. Ward ML, Crossman DJ. Mechanisms underlying the impaired contractility of diabetic cardiomyopathy. World J Cardiol 2014; 6: 577–584
- 32. Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol 1983; 244: E528–E535
- 33. Seeger H, Lippert C, Wallwiener D, Mueck AO. Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function. J Renin Angiotensin Aldosterone Syst 2001; 2: 141–143
- 34. Khanna S, Singh GB, Khullar M. Nitric oxide synthases and diabetic cardiomyopathy. Nitric Oxide 2014; 1: 29–34
- 35. Janssen S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004; 94: 1256–1262
- 36. Ichinose F, Bloch KD, Wu JC, Hataishi R, Aretz HT, Picard MH et al. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol 2004; 286: H1070–H1075
- 37. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001; 104: 1286–1291
- 38. Nagareddy PR, Xia Z, McNeill JH, MacLeod KM. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Physiol Heart Circ Physiol. 2005; 289: H2144–H2152
- 39. West MB, Ramana KV, Kaiserova K, Sirvastava SK, Bhatngar A. L-Arginin prevents metabolic effects of high glucose in diabetic mice. FEBS let. 2008; 582: 2609–2614
- 40. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the reninangiotensin system. Am J Hypertens. 2004; 17: 597–603